McDermott advises Innate Pharma on its strategic partnership with Sobi to license lacutamab

McDermott Will & Schulte advised Innate Pharma on its strategic partnership with Sobi to license lacutamab, its anti-KIR3DL2 antibody, in T-cell lymphoma.

This partnership represents an important step intended to enable initiation of the TELLOMAK-3 confirmatory phase 3 Study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sezary syndrome.

The McDermott Will & Schulte team comprised:

• Emmanuelle Trombe, Anne-France Moreau, partners, Alice Villagrasa, associate (Paris), and Monika Richter, partner (Frankfurt), on Life Sciences / Transaction aspects
• Stéphane Dionnet, partner, and Ángela Fernández de la Puebla, associate (Brussels), Jon Dubrow, partner, Ty Carson, Counsel, and Megan Ingram, associate (Washington), on Antitrust aspects